Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
María E. Ruiz, Melisa E. Gantner and Alan Talevi
Affiliation: Biopharmacy, Department of Biological Sciences, Faculty of Exact Sciences, National University of La Plata (UNLP) – Argentinean National Council for Scientific and Technical Research (CONICET) CCT La Plata. 47 and 115, La Plata (B1900AJI), Buenos Aires, Argentina.
Keywords: Anticancer drug therapy, dendrimers, lipid-based nanosystems, liposomes, micelles, nanostructured lipid carriers,
patents, solid lipid nanocarriers.
The great efforts of many researchers have brought down some of the barriers that exist to turn a good in vitro
compound into a potential in vivo drug. The advent of pharmaceutical nanotechnology has allowed an arsenal of drugs
with poor stability, low solubility, high off-target toxicity and other disadvantageous features, to be accessible as pharmaceutical
products that could be administered to a patient. Nanotechnology was introduced in drug delivery very long ago,
but has flourished with unprecedented intensity during the last twenty years and now a diversity of nano-based preparations
are at clinical stage of development or already available in the market. Undoubtedly, nanotechnology plays a key
role in future pharmaceutical development and pharmacotherapy. In the first part of this review, we have already discussed
recent (2008-2012) patents on linear polymer-based nanosystems (nanogels, nanospheres and nanocapsules) applications
to cancer therapy. Here, we have expanded such analysis to branched polymers (dendrimers), self-assembling
nanomicelles and lipid-based nanocarriers.
Rights & PermissionsPrintExport